Pfizer Inc. (PFE) Shares Bought by Schaper Benz & Wise Investment Counsel Inc. WI
Schaper Benz & Wise Investment Counsel Inc. WI lifted its stake in shares of Pfizer Inc. (NYSE:PFE) by 2.8% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 224,950 shares of the biopharmaceutical company’s stock after purchasing an additional 6,088 shares during the period. Schaper Benz & Wise Investment Counsel Inc. WI’s holdings in Pfizer were worth $8,031,000 as of its most recent filing with the SEC.
Other hedge funds also recently modified their holdings of the company. Shine Investment Advisory Services Inc. bought a new position in Pfizer in the second quarter worth about $102,000. Mckinley Capital Management LLC Delaware bought a new position in Pfizer in the second quarter worth about $103,000. D. Scott Neal Inc. lifted its holdings in Pfizer by 19.3% in the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after acquiring an additional 504 shares during the last quarter. Herndon Capital Management LLC bought a new position in Pfizer in the second quarter worth about $120,000. Finally, Lipe & Dalton lifted its holdings in Pfizer by 6.9% in the second quarter. Lipe & Dalton now owns 4,626 shares of the biopharmaceutical company’s stock worth $155,000 after acquiring an additional 300 shares during the last quarter. 69.75% of the stock is currently owned by institutional investors and hedge funds.
In related news, EVP Rady A. Johnson sold 8,000 shares of the firm’s stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $37.07, for a total transaction of $296,560.00. Following the transaction, the executive vice president now owns 46,963 shares in the company, valued at $1,740,918.41. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Alexander R. Mackenzie sold 14,700 shares of the firm’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $35.30, for a total transaction of $518,910.00. Following the transaction, the insider now owns 117,432 shares in the company, valued at approximately $4,145,349.60. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 29,450 shares of company stock worth $1,065,220. Corporate insiders own 0.06% of the company’s stock.
Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.02. The company had revenue of $13.17 billion for the quarter, compared to analysts’ expectations of $13.17 billion. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The business’s revenue for the quarter was up .9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.61 earnings per share. sell-side analysts forecast that Pfizer Inc. will post 2.59 EPS for the current year.
Pfizer declared that its board has approved a share buyback plan on Monday, December 18th that authorizes the company to buyback $10.00 billion in outstanding shares. This buyback authorization authorizes the biopharmaceutical company to buy shares of its stock through open market purchases. Stock buyback plans are typically a sign that the company’s board of directors believes its shares are undervalued.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, February 2nd will be issued a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.68%. The ex-dividend date of this dividend is Thursday, February 1st. This is a boost from Pfizer’s previous quarterly dividend of $0.32. Pfizer’s payout ratio is 78.53%.
A number of equities analysts have issued reports on PFE shares. BMO Capital Markets set a $39.00 target price on shares of Pfizer and gave the stock a “buy” rating in a report on Tuesday, October 31st. UBS Group set a $38.00 target price on shares of Pfizer and gave the stock a “buy” rating in a report on Wednesday, November 1st. Barclays set a $38.00 target price on shares of Pfizer and gave the stock a “buy” rating in a report on Wednesday, October 11th. ValuEngine raised shares of Pfizer from a “hold” rating to a “buy” rating in a report on Friday, October 6th. Finally, Zacks Investment Research raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $40.00 target price on the stock in a report on Tuesday, October 3rd. Two analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $38.94.
TRADEMARK VIOLATION WARNING: “Pfizer Inc. (PFE) Shares Bought by Schaper Benz & Wise Investment Counsel Inc. WI” was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright law. The correct version of this piece of content can be accessed at https://theolympiareport.com/2018/01/19/pfizer-inc-pfe-shares-bought-by-schaper-benz-wise-investment-counsel-inc-wi.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.